A Practitioner’s Guide to Prescribing Levetiracetam for Adults with Intellectual Disabilities

  • Jose de Leon
Chapter

Abstract

We developed this levetiracetam guideline using drug prescribing ­information and reviewing the available literature on relevant neuropsychiatric disorders in populations without intellectual disabilities because of the dearth of available literature on the population with intellectual disabilities. This guideline includes indications, contraindications, assessments prior to and during treatment, dosing with particular focus on dosing modifications required by drug–drug interactions or personal characteristics, and adverse drug reactions. The procedures contained in this guideline may not fully account for all of the possible risks of treatment in this population because of the limited studies available; thus, there will be a need to periodically update this guideline as new information becomes available. Nevertheless, we believe that this guideline provides a useful resource for clinicians who treat epilepsy in adult individuals with intellectual disabilities. A levetiracetam drug utilization review that summarizes this guideline is described.

Keywords

Placebo Depression Warfarin Digoxin Carbamazepine 

References

  1. Abou-Khalil, B. (2005). Benefit-risk assessment of levetiracetam in the treatment of partial ­seizures. Drug Safety, 28, 871–890.PubMedCrossRefGoogle Scholar
  2. Abou-Khalil, B. (2008). Levetiracetam in the treatment of epilepsy. Neuropsychiatric Disease and Treatment, 4, 507–523.PubMedCrossRefGoogle Scholar
  3. Arana, A., Wentworth, C. E., Ayuso-Mateos, J. L., & Arellano, F. M. (2010). Suicide-related events in patients treated with antiepileptic drugs. The New England Journal of Medicine, 363, 542–551.PubMedCrossRefGoogle Scholar
  4. Arif, H., Buchsbaum, R., Pierro, J., Whalen, M., Sims, J., Resor, S. R., Jr., et al. (2010). Comparative effectiveness of 10 antiepileptic drugs in older adults with epilepsy. Archives of Neurology, 67, 408–415.PubMedCrossRefGoogle Scholar
  5. Arif, H., Buchsbaum, R., Weintraub, D., Koyfman, S., Salas-Humara, C., Bazil, C. W., et al. (2007). Comparison and predictors of rash associated with 15 antiepileptic drugs. Neurology, 68, 1701–1709.PubMedCrossRefGoogle Scholar
  6. Arif, H., Buchsbaum, R., Weintraub, D., Pierro, J., Resor, S. R., Jr., & Hirsch, L. J. (2009). Patient-reported cognitive side effects of antiepileptic drugs: predictors and comparison of all commonly used antiepileptic drugs. Epilepsy & Behavior, 14, 202–209.CrossRefGoogle Scholar
  7. Arroyo, S., & Crawford, P. (2003). Safety profile of levetiracetam. Epileptic Disorders, 5(Suppl 1), S57–S63.PubMedGoogle Scholar
  8. Beavis, J., Meek, A., Felce, D., & Kerr, M. (2009). A prospective multi-centre open label study of the use of levetiracetam as add-on treatment in patients with epilepsy and intellectual disabilities. Seizure, 4, 279–284.CrossRefGoogle Scholar
  9. Belcastro, V., Costa, C., & Striano, P. (2008). Levetiracetam-associated hyponatremia (letter). Seizure, 17, 389–390.PubMedCrossRefGoogle Scholar
  10. Bell, G. S., Mula, M., & Sander, J. W. (2009). Suicidality in people taking antiepileptic drugs: what is the evidence? CNS Drugs, 23, 281–292.PubMedCrossRefGoogle Scholar
  11. Ben-Menachem, E. (2007). Weight issues for people with epilepsy – a review. Epilepsia, 48(Suppl 9), 42–45.PubMedCrossRefGoogle Scholar
  12. Bilo, L., Meo, R., de Leva, M. F., De Simone, R., Di Nocera, P., Pisani, F., et al. (2008). Levetiracetam in patients with epilepsy and chronic liver disease: observations in a case series. Clinical Neuropharmacology, 31, 221–225.PubMedCrossRefGoogle Scholar
  13. Bootsma, H. P., Aldenkamp, A. P., Diepman, L., Hulsman, J., Lambrechts, D., Leenen, L., et al. (2006). The effect of antiepileptic drugs on cognition: patient perceived cognitive problems of topiramate versus levetiracetam in clinical practice. Epilepsia, 47(Suppl 2), 24–27.PubMedCrossRefGoogle Scholar
  14. Brockmöller, J., Thomsen, T., Wittstock, M., Coupez, R., Lochs, H., & Roots, I. (2005). Pharmacokinetics of levetiracetam in patients with moderate to severe liver cirrhosis (Child-Pugh classes A, B, and C): characterization by dynamic liver function tests. Clinical Pharmacology and Therapeutics, 77, 529–541.PubMedCrossRefGoogle Scholar
  15. Brodtkorb, E., Klees, T. M., Nakken, K. O., Lossius, R., & Johannessen, S. I. (2004). Levetiracetam in adult patients with and without learning disability: focus on behavioral adverse effects. Epilepsy & Behavior, 5, 231–235.CrossRefGoogle Scholar
  16. Carpay, J. A., Aalbers, K., Graveland, G. A., & Engelsman, M. (2009). Retention of new AEDs in institutionalized intellectually disabled patients with epilepsy. Seizure, 18, 119–123.PubMedCrossRefGoogle Scholar
  17. Chaisewikul, R., Privitera, M. D., Hutton, J. L., Marson, A. G. (2001). Levetiracetam add-on for drug-resistant localization related (partial) epilepsy. The Cochrane Database of Systematic Reviews, 1, CD001901.Google Scholar
  18. Chouinard, M. J., Nguyen, D. K., Clément, J. F., & Bruneau, M. A. (2006). Catatonia induced by levetiracetam. Epilepsy & Behavior, 8, 303–307.CrossRefGoogle Scholar
  19. Contin, M., Albani, F., Riva, R., & Baruzzi, A. (2004). Levetiracetam therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs. Therapeutic Drug Monitoring, 26, 375–379.PubMedCrossRefGoogle Scholar
  20. Cramer, J. A., De Rue, K., Devinsky, O., Edrich, P., & Trimble, M. R. (2003). A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials. Epilepsy & Behavior, 4, 124–132.CrossRefGoogle Scholar
  21. De Smedt, T., Raedt, R., Vonck, K., & Boon, P. (2007). Levetiracetam: part II, the clinical profile of a novel anticonvulsant drug. CNS Drug Reviews, 13, 57–78.PubMedCrossRefGoogle Scholar
  22. Deb, S., & Kaur Saini, S. T. (2007). Levetiracetam for the treatment of epilepsy among adults with intellectual disabilities (letter). Journal of Intellectual Disability Research, 51, 564–565.PubMedCrossRefGoogle Scholar
  23. Dericioglu, N., & Saygi, S. (2010). Generalized seizures aggravated by levetiracetam in an adult patient with phenylketonuria. Metabolic Brain Disease, 25, 207–209.PubMedCrossRefGoogle Scholar
  24. Dinkelacker, V., Dietl, T., Widman, G., Lengler, U., & Elger, C. E. (2003). Aggressive behavior of epilepsy patients in the course of levetiracetam add-on therapy: report of 33 mild to severe cases. Epilepsy & Behavior, 4, 537–547.CrossRefGoogle Scholar
  25. Epstein, C. M., Girard-Siqueira, L., & Ehrenberg, J. A. (2008). Prolonged neurophysiologic effects of levetiracetam after oral administration in humans. Epilepsia, 49, 1169–1173.PubMedCrossRefGoogle Scholar
  26. Evcimen, H., Kushon, D., & Jenssen, S. (2007). Nonepileptic hallucinations in use of levetiracetam (letter). Psychosomatics, 48, 548–549.PubMedCrossRefGoogle Scholar
  27. Farooq, M. U., Bhatt, A., Majid, A., Gupta, R., Khasnis, A., & Kassab, M. Y. (2009). Levetiracetam for managing neurologic and psychiatric disorders. American Journal of Health-System Pharmacy, 66, 541–561.PubMedCrossRefGoogle Scholar
  28. Gambardella, A., Labate, A., Colosimo, E., Ambrosio, R., & Quattrone, A. (2008). Monotherapy for partial epilepsy: focus on levetiracetam. Neuropsychiatric Disease and Treatment, 4, 33–38.PubMedCrossRefGoogle Scholar
  29. Gelisse, P., Juntas-Morales, R., Genton, P., Hillaire-Buys, D., Diaz, O., Coubes, P., et al. (2008). Dramatic weight loss with levetiracetam. Epilepsia, 49, 308–315.PubMedCrossRefGoogle Scholar
  30. Gidal, B. E., Baltès, E., Otoul, C., & Perucca, E. (2005). Effect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: a pooled analysis of data from randomized clinical trials. Epilepsy Research, 64, 1–11.PubMedCrossRefGoogle Scholar
  31. Gidal, B. E., Sheth, R. D., Magnus, L., & Herbeuval, A. F. (2003). Levetiracetam does not alter body weight: analysis of randomized, controlled clinical trials. Epilepsy Research, 56, 121–126.PubMedCrossRefGoogle Scholar
  32. Gomer, B., Wagner, K., Frings, L., Saar, J., Carius, A., Härle, M., et al. (2007). The influence of antiepileptic drugs on cognition: a comparison of levetiracetam with topiramate. Epilepsy & Behavior, 10, 486–494.CrossRefGoogle Scholar
  33. Grim, S. A., Ryan, M., Miles, M. V., Tang, P. H., Strawsburg, R. H., deGrauw, T. J., et al. (2003). Correlation of levetiracetam concentrations between serum and saliva. Therapeutic Drug Monitoring, 25, 61–66.PubMedCrossRefGoogle Scholar
  34. Hadjikoutis, S., Pickersgill, T. P., & Smith, P. E. (2003). Drug points: weight loss associated with levetiracetam. British Medical Journal, 327, 905.PubMedCrossRefGoogle Scholar
  35. Harris, E. C., & Barraclough, B. (1997). Suicide as an outcome for mental disorders. A meta-analysis. The British Journal of Psychiatry, 170, 205–228.PubMedCrossRefGoogle Scholar
  36. Helmstaedter, C., Fritz, N. E., Kockelmann, E., Kosanetzky, N., & Elger, C. E. (2008). Positive and negative psychotropic effects of levetiracetam. Epilepsy & Behavior, 13, 535–541.CrossRefGoogle Scholar
  37. Hesdorffer, D. C., Berg, A. T., & Kanner, A. M. (2010). An update on antiepileptic drugs and suicide: are there definitive answers yet? Epilepsy Currents, 10, 137–145.PubMedGoogle Scholar
  38. Hirsch, L. J., Arif, H., Buchsbaum, R., Weintraub, D., Lee, J., Chang, J. T., et al. (2007). Effect of age and comedication on levetiracetam pharmacokinetics and tolerability. Epilepsia, 48, 1351–1359.PubMedCrossRefGoogle Scholar
  39. Huang, C. W., Pai, M. C., & Tsai, J. J. (2008). Comparative cognitive effects of levetiracetam and topiramate in intractable epilepsy. Psychiatry and Clinical Neurosciences, 62, 548–553.PubMedCrossRefGoogle Scholar
  40. Huber, B., Bömmel, W., Hauser, I., Horstmann, V., Liem, S., May, T., et al. (2004). Efficacy and tolerability of levetiracetam in patients with therapy-resistant epilepsy and learning disabilities. Seizure, 13, 168–175.PubMedCrossRefGoogle Scholar
  41. Hurtado, B., Koepp, M. J., Sander, J. W., & Thompson, P. J. (2006). The impact of levetiracetam on challenging behavior. Epilepsy & Behavior, 8, 588–592.CrossRefGoogle Scholar
  42. Johannessen, S. I., & Tomson, T. (2006). Pharmacokinetic variability of newer antiepileptic drugs. When is monitoring needed? Clinical Pharmacokinetics, 45, 1061–1075.PubMedCrossRefGoogle Scholar
  43. Kalanin, V. V. (2007). Suicidality and antiepileptic drugs. Is there a link? Drug Safety, 30, 123–142.CrossRefGoogle Scholar
  44. Kelly, K., Stephen, L. J., & Brodie, M. J. (2004). Levetiracetam for people with mental retardation and refractory epilepsy. Epilepsy & Behavior, 6, 878–883.CrossRefGoogle Scholar
  45. Kimland, E., Höjeberg, B., & von Euler, M. (2004). Levetiracetam-induced thrombocytopenia. Epilepsia, 45, 877–878.PubMedCrossRefGoogle Scholar
  46. Kuehn, B. M. (2008). FDA warns of adverse events linked to smoking cessation drug and antiepileptics. The Journal of the American Medical Association, 299, 1121–1122.CrossRefGoogle Scholar
  47. Labiner, D. M., Ettinger, A. B., Fakhoury, T. A., Chung, S. S., Shneker, B., Tatum Iv, W. O., et al. (2009). Effects of lamotrigine compared with levetiracetam on anger, hostility, and total mood in patients with partial epilepsy. Epilepsia, 50, 434–442.PubMedCrossRefGoogle Scholar
  48. Lacy, C. F., Armstrong, L. L., Goldman, M. P., & Lance, L. L. (2009). Drug information handbook (18th ed.). Hudson, OH: Lexi-Comp Inc.Google Scholar
  49. Levy, R. H., Ragueneau-Majlessi, I., & Baltes, E. (2001). Repeated administration of the novel antiepileptic agent levetiracetam does not alter digoxin pharmacokinetics and pharmacodynamics in healthy volunteers. Epilepsy Research, 46, 93–99.PubMedCrossRefGoogle Scholar
  50. López-Fraile, I. P., Cid, A. O., Juste, A. O., & Modrego, P. J. (2009). Levetiracetam plasma level monitoring during pregnancy, delivery, and postpartum: clinical and outcome implications. Epilepsy & Behavior, 15, 372–375.CrossRefGoogle Scholar
  51. Lynch, B. A., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S. M., Matagne, A., et al. (2004). The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proceedings of the National Academy of Sciences of the United States of America, 101, 9861–9866.PubMedCrossRefGoogle Scholar
  52. Marson, A. G., Hutton, J. L., Leach, J. P., Castillo, S., Schmidt, D., White, S., et al. (2001). Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistant localization-related epilepsy: a systematic review. Epilepsy Research, 46, 259–270.PubMedCrossRefGoogle Scholar
  53. May, T. W., Korn-Merker, E., & Rambeck, B. (2003). Clinical pharmacokinetics of oxcarbazepine. Clinical Pharmacokinetics, 42, 1023–1042.PubMedCrossRefGoogle Scholar
  54. May, T. W., Rambeck, B., & Jürgens, U. (2003). Serum concentrations of levetiracetam in epileptic patients: the influence of dose and co-medication. Therapeutic Drug Monitoring, 25, 690–699.PubMedCrossRefGoogle Scholar
  55. Mecarelli, O., Vicenzini, E., Pulitano, P., Vanacore, N., Romolo, F. S., Di Piero, V., et al. (2004). Clinical, cognitive, and neurophysiologic correlates of short-term treatment with carbamazepine, oxcarbazepine, and levetiracetam in healthy volunteers. The Annals of Pharmacotherapy, 38, 1816–1822.PubMedCrossRefGoogle Scholar
  56. Merrick, J., Merrick, E., Lunsky, Y., & Kandel, I. (2006). A review of suicidality in persons with intellectual disability. The Israel Journal of Psychiatry and Related Sciences, 43, 258–264.PubMedGoogle Scholar
  57. Meschede, A., Runge, U., & Sabolek, M. (2008). Thrombocytopenia during levetiracetam therapy. Epilepsy Research, 80, 91–92.PubMedCrossRefGoogle Scholar
  58. Mula, M., & Sander, J. W. (2007a). Negative effects of antiepileptic drugs on mood in patients with epilepsy. Drug Safety, 30, 555–567.PubMedCrossRefGoogle Scholar
  59. Mula, M., & Sander, J. W. (2007b). Suicidal ideation in epilepsy and levetiracetam therapy. Epilepsy & Behavior, 11, 130–132.CrossRefGoogle Scholar
  60. Mula, M., Trimble, M. R., & Sander, J. W. (2004). Psychiatric adverse events in patients with epilepsy and learning disabilities taking levetiracetam. Seizure, 13, 55–57.PubMedCrossRefGoogle Scholar
  61. Mula, M., Trimble, M. R., & Sander, J. W. (2007). Are psychiatric adverse events of antiepileptic drugs a unique entity? A study on topiramate and levetiracetam. Epilepsia, 48, 2322–2326.PubMedGoogle Scholar
  62. Muralidharan, A., & Bhagwagar, Z. (2006). Potential of levetiracetam in mood disorders: a preliminary review. CNS Drugs, 20, 969–979.PubMedCrossRefGoogle Scholar
  63. Nasrallah, K., & Silver, B. (2005). Hyponatremia associated with repeated use of levetiracetam. Epilepsia, 46, 972–973.PubMedCrossRefGoogle Scholar
  64. Otoul, C., Arrigo, C., van Rijckevorsel, K., & French, J. A. (2005). Meta-analysis and indirect comparisons of levetiracetam with other second-generation antiepileptic drugs in partial epilepsy. Clinical Neuropharmacology, 28, 72–78.PubMedCrossRefGoogle Scholar
  65. Patsalos, P. N. (2004). Clinical pharmacokinetics of levetiracetam. Clinical Pharmacokinetics, 43, 707–724.PubMedCrossRefGoogle Scholar
  66. Patsalos, P. N., Berry, D. J., Bourgeois, B. F., Cloyd, J. C., Glauser, T. A., Johannessen, S. I., et al. (2008). Antiepileptic drugs – best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia, 49, 1239–1276.PubMedCrossRefGoogle Scholar
  67. Perucca, E., Gidal, B. E., & Baltès, E. (2003). Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. Epilepsy Research, 53, 47–56.PubMedCrossRefGoogle Scholar
  68. Pigeolet, E., Jacqmin, P., Sargentini-Maier, M. L., & Stockis, A. (2007). Population pharmacokinetics of levetiracetam in Japanese and Western adults. Clinical Pharmacokinetics, 46, 503–512.PubMedCrossRefGoogle Scholar
  69. Ragueneau-Majlessi, I., Levy, R. H., & Janik, F. (2002). Levetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy women. Epilepsia, 43, 697–702.PubMedCrossRefGoogle Scholar
  70. Ragueneau-Majlessi, I., Levy, R. H., & Meyerhoff, C. (2001). Lack of effect of repeated administration of levetiracetam on the pharmacodynamic and pharmacokinetic profiles of warfarin. Epilepsy Research, 47, 55–63.PubMedCrossRefGoogle Scholar
  71. Rogwaski, M. A., & Löscher, W. (2004). The neurobiology of antiepileptic drugs. Nature Reviews. Neuroscience, 5, 553–564.CrossRefGoogle Scholar
  72. Rouits, E., Burton, I., Guénolé, E., Troenaru, M. M., Stockis, A., & Sargentini-Maier, M. L. (2009). Pharmacokinetics of levetiracetam XR 500 mg tablets. Epilepsy Research, 4, 224–231.CrossRefGoogle Scholar
  73. Sahaya, K., Goyal, M. K., Sarwal, A., & Singh, N. N. (2010). Levetiracetam-induced thrombocytopenia among inpatients: a retrospective study. Epilepsia, 51, 2492–2495.PubMedCrossRefGoogle Scholar
  74. Sangani, M., Shahid, A., Amina, S., & Koubeissi, M. (2010). Improvement of myoclonic epilepsy in Down syndrome treated with levetiracetam. Epileptic Disorders, 12, 151–154.PubMedGoogle Scholar
  75. Saponara, R., Greco, S., Proto, G., Trubia, T., & Domina, E. (2009). Levetiracetam improves intention tremor in fragile x-associated tremor/ataxia syndrome. Clinical Neuropharmacology, 32, 53–54.PubMedCrossRefGoogle Scholar
  76. Shallcross, R., Bromley, R. L., Irwin, B., Bonnett, L. J., Morrow, J., Baker, G. A., et al. (2011). Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology, 76, 383–389.PubMedCrossRefGoogle Scholar
  77. Simister, R. J., Sander, J. W., & Koepp, M. J. (2007). Long-term retention rates of new antiepileptic drugs in adults with chronic epilepsy and learning disability. Epilepsy & Behavior, 2, 336–339.CrossRefGoogle Scholar
  78. Sirven, J. I., Fife, T. D., Wingerchuk, D. M., & Drazkowski, J. F. (2007). Second-generation antiepileptic drugs’ impact on balance: a meta-analysis. Mayo Clinic Proceedings, 82, 40–47.PubMedGoogle Scholar
  79. Specchio, N., Balestri, M., Striano, P., Cilio, M. R., Nardello, R., Patanè, S., et al. (2010). Efficacy of levetiracetam in the treatment of drug-resistant Rett syndrome. Epilepsy Research, 88, 112–117.PubMedCrossRefGoogle Scholar
  80. Stein, M. B., Ravindran, L. N., Simon, N. M., Liebowitz, M. R., Khan, A., Brawman-Mintzer, O., et al. (2010). Levetiracetam in generalized social anxiety disorder: a double-blind, randomized controlled trial. The Journal of Clinical Psychiatry, 71, 627–631.PubMedCrossRefGoogle Scholar
  81. Szucs, A., Clemens, Z., Jakus, R., Rásonyi, G., Fabó, D., Holló, A., et al. (2008). The risk of paradoxical levetiracetam effect is increased in mentally retarded patients. Epilepsia, 49, 1174–1179.PubMedCrossRefGoogle Scholar
  82. Tan, T. C., de Boer, B. W., Mitchell, A., Delriviere, L., Adams, L. A., Jeffrey, G. P., et al. (2008). Levetiracetam as a possible cause of fulminant liver failure. Neurology, 71, 685–686.PubMedCrossRefGoogle Scholar
  83. Thibert, R. L., Conant, K. D., Braun, E. K., Bruno, P., Said, R. R., Nespeca, M. P., et al. (2009). Epilepsy in Angelman syndrome: a questionanaire-based assessment of the natural history and current treatment options. Epilepsia, 50, 2369–2376.PubMedCrossRefGoogle Scholar
  84. Tomson, T., Palm, R., Källén, K., Ben-Menachem, E., Söderfeldt, B., Danielsson, B., et al. (2007). Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period, and lactation. Epilepsia, 48, 1111–1116.PubMedCrossRefGoogle Scholar
  85. UCB Inc. (2009a). Keppra-levetiracetam tablet, film coated. Keppra-levetiracetam solution. ­(prescribing information). Smyrna, GA: UCB Inc.Google Scholar
  86. UCB Inc. (2009b). Keppra XR (levetiracetam) tablet, film coated, extended release tablets for oral use (highlights of prescribing information). Smyrna, GA: UCB Inc.Google Scholar
  87. US Department of Mental Health and Human Services. (2008). Statistical review and evaluation: Antiepileptic drugs and suicidality. http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4372b1-01-FDA.pdf. Accessed 5 April 2011.
  88. van Rijckevorsel, K., & Boon, P. A. (2001). The ‘number needed to treat’ with levetiracetam (LEV): comparison with the other new antiepileptic drugs (AEDs) (letter). Seizure, 10, 235–236.PubMedCrossRefGoogle Scholar
  89. Vande Griend, J. P., Linnebur, S. A., & Bainbridge, J. L. (2009). Probable levetiracetam-associated depression in the elderly: two case reports. The American Journal of Geriatric Pharmacotherapy, 7, 281–284.PubMedCrossRefGoogle Scholar
  90. Wasserman, S., Iyengar, R., Chaplin, W. F., Watner, D., Waldoks, S. E., Anagnostou, E., et al. (2006). Levetiracetam versus placebo in childhood and adolescent autism: a double-blind ­placebo-controlled study. International Clinical Psychopharmacology, 21, 363–367.PubMedCrossRefGoogle Scholar
  91. Weintraub, D., Buchsbaum, R., Resor, S. R., Jr., & Hirsch, L. J. (2007). Psychiatric and behavioral side effects of the newer antiepileptic drugs in adults with epilepsy. Epilepsy & Behavior, 10, 105–110.CrossRefGoogle Scholar
  92. Westin, A. A., Reimers, A., Helde, G., Nakken, K. O., & Brodtkorb, E. (2008). Serum concentration/dose ratio of levetiracetam before, during and after pregnancy. Seizure, 17, 192–198.PubMedCrossRefGoogle Scholar
  93. White, J. R., Walczak, T. S., Leppik, I. E., Rarick, J., Tran, T., Beniak, T. E., et al. (2003). Discontinuation of levetiracetam because of behavioral side effects: a case–control study. Neurology, 61, 1218–1221.PubMedGoogle Scholar
  94. Woods, S. W., Saksa, J. R., Baker, C. B., Cohen, S. J., & Tek, C. (2008). Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. The Journal of Clinical Psychiatry, 69, 546–554.PubMedCrossRefGoogle Scholar
  95. Zaatreh, M. M. (2003). Anticonvulsant-induced dyskinesia. Expert Opinion on Drug Safety, 2, 385–393.PubMedCrossRefGoogle Scholar
  96. Zaccara, G., Gangemi, P. F., & Cincotta, M. (2008). Central nervous system adverse effects of new antiepileptic drugs. A meta-analysis of placebo-controlled studies. Seizure, 17, 405–421.PubMedCrossRefGoogle Scholar
  97. Zaccara, G., Messori, A., Cincotta, M., & Burchini, G. (2006). Comparison of the efficacy and tolerability of new antiepileptic drugs: what can we learn from long-term studies? Acta Neurologica Scandinavica, 114, 157–168.PubMedCrossRefGoogle Scholar
  98. Zesiewicz, T. A., Sullivan, K. L., Hauser, R. A., & Sanchez-Ramos, J. (2006). Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington’s disease. Movement Disorders, 21, 1998–2001.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Jose de Leon
    • 1
  1. 1.Department of Psychiatry College of MedicineUniversity of KentuckyLexingtonUSA

Personalised recommendations